- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:48 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA | 1 | GlobeNewswire (USA) | ||
| 27.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program | 1 | GlobeNewswire (USA) | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 11.12.25 | Ernexa Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Ernexa Therapeutics: Aktie fällt trotz positiver Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board | 1 | Investing.com | ||
| 02.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG | 1 | GlobeNewswire (USA) | ||
| 11.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Present at Oxford Global's Cell 2025 | 2 | GlobeNewswire (USA) | ||
| 10.11.25 | Eterna Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 10.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials | 134 | GlobeNewswire (Europe) | The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program... ► Artikel lesen | |
| 07.11.25 | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform | 1 | GlobeNewswire (USA) | ||
| 29.10.25 | Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer | 168 | PR Newswire | THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization... ► Artikel lesen | |
| 29.10.25 | Ernexa Therapeutics stock soars after Cellipont manufacturing deal | 3 | Investing.com | ||
| 29.10.25 | Ernexa Therapeutics: Aktie schießt nach Produktionsvereinbarung mit Cellipont in die Höhe | 5 | Investing.com Deutsch | ||
| 01.10.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) | ||
| 29.09.25 | Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy Company | 2 | pulse2.com | ||
| 29.09.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,035 | -0,06 % | Qiagen beruft Mark Stevenson in den Aufsichtsrat | DJ Qiagen beruft Mark Stevenson in den Aufsichtsrat
DOW JONES--Qiagen hat Mark Stevenson als Nachfolger von Ross Levine mit Wirkung zum vergangenen Freitag in den Aufsichtsrat berufen. Stevenson... ► Artikel lesen | |
| EVOTEC | 6,460 | +9,49 % | Evotec Aktie: Comebacktitel für 2026? | Aktionäre von Evotec müssen viel Geduld aufbringen. Seit Monaten scheitern immer wieder die Versuche der Biotech-Aktie, stabil über die 200-Tage-Linie zu springen. An oder knapp oberhalb des viel beachteten... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,21 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 91,05 | -1,46 % | BioNTech-Aktie: Hält das starke Momentum? | Die BioNTech-Aktie meldet sich 2026 eindrucksvoll zurück. Seit Jahresbeginn liegt der Titel um rund 23% im Plus, notiert bei knapp 120 US$ und zählt damit zu den auffälligen Gewinnern an der Börse.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,070 | -2,52 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 83,44 | -7,12 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| PRAXIS PRECISION MEDICINES | 311,00 | +0,61 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| TANGO THERAPEUTICS | 12,570 | +5,45 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| ERASCA | 10,500 | -1,04 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| SUMMIT THERAPEUTICS | 14,440 | +2,70 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| IMMUNOME | 26,880 | +2,83 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| KYMERA THERAPEUTICS | 77,14 | +2,01 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,760 | -0,05 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| MINERALYS THERAPEUTICS | 31,120 | +0,91 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| MAZE THERAPEUTICS | 47,825 | +2,76 % | Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,955 Euro und damit -22,98 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.